| Description | Omarigliptin (MK-3102) has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Chronic Renal Insufficiency. |
| Target activity | DPP4:1.6 nM |
| Synonyms | MK-3102, 奥格列汀 |
| molecular weight | 398.43 |
| Molecular formula | C17H20F2N4O3S |
| CAS | 1226781-44-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 50 mg/mL (125.49 mM) |
| References | 1. Biftu T, et al. J Med Chem. 2014 Apr 24;57(8):3205-12. 2. Du H, Wang S. Omarigliptin Mitigates Lipopolysaccharide-Induced Neuroinflammation and Dysfunction of the Integrity of the Blood–Brain Barrier[J]. ACS Chemical Neuroscience. 2020 |
| Citations | 1. Du H, Wang S Omarigliptin Mitigates Lipopolysaccharide-Induced Neuroinflammation and Dysfunction of the Integrity of the Blood–Brain Barrier. ACS Chemical Neuroscience. 2020 2. Heo R, Kang M, Mun S Y, et al. Antidiabetic Omarigliptin Dilates Rabbit Aorta by Activating Kv Channels and the SERCA Pump. Fundamental & Clinical Pharmacology. 2022 3. Heo R, Kang M, Mun S Y, et al.Antidiabetic omarigliptin dilates rabbit aorta by activating voltage‐dependent K+ channels and the sarco/endoplasmic reticulum Ca2+‐ATPase pump.Fundamental & Clinical Pharmacology.2023, 37(1): 75-84. |